Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays

被引:239
作者
La Marca, Antonio [1 ]
Capuzzo, Martina [1 ]
Paglia, Tiziana [2 ]
Roli, Laura [3 ]
Trenti, Tommaso [3 ]
Nelson, Scott M. [4 ,5 ,6 ]
机构
[1] Univ Modena & Reggio Emilia, Dept Med & Surg Sci Children & Adults, Modena, Italy
[2] Hesperia Hosp, Dept Anesthesiol, Modena, Italy
[3] Azieda USL, Dept Lab Med & Pathol, Modena, Italy
[4] Univ Glasgow, Sch Med, Glasgow, Lanark, Scotland
[5] NIHR Bristol Biomed Res Ctr Bristol, Bristol, Avon, England
[6] Fertil Partnership, Oxford, England
关键词
Antibody testing; COVID-19; Diagnostic test; SARS-CoV-2; Serology; ENZYME-IMMUNOASSAY; IGG ANTIBODIES; SENSITIVITY; RESPONSES; ANTIGEN; SERA;
D O I
10.1016/j.rbmo.2020.06.001
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated coronavirus disease 2019 (COVID-19) pandemic has demanded rapid upscaling of in-vitro diagnostic assays to enable mass screening and testing of high-risk groups, and simultaneous ascertainment of robust data on past SARS-CoV-2 exposure at an individual and a population level. To meet the exponential demand in testing, there has been an accelerated development of both molecular and serological assays across a plethora of platforms. The present review discusses the current literature on these modalities, including nucleic acid amplification tests, direct viral antigen tests and the rapidly expanding laboratory-based and point of care serological tests. This suite of complementary tests will inform crucial decisions by healthcare providers and policy makers, and understanding their strengths and limitations will be critical to their judicious application for the development of algorithmic approaches to treatment and public health strategies.
引用
收藏
页码:483 / 499
页数:17
相关论文
共 97 条
[31]  
Hu Q, 2020, PRODUCTION ANTIBODIE, DOI [10.1101/2020.04.20.20065953, DOI 10.1101/2020.04.20.20065953]
[32]   Epidemiology and Clinical Characteristics of COVID-19 [J].
Huang, Xiaoyi ;
Wei, Fengxiang ;
Hu, Liang ;
Wen, Lijuan ;
Chen, Ken .
ARCHIVES OF IRANIAN MEDICINE, 2020, 23 (04) :268-271
[33]  
Imai Kazuo, 2020, J Clin Virol, V128, P104393, DOI 10.1016/j.jcv.2020.104393
[34]   Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience [J].
Infantino, Maria ;
Grossi, Valentina ;
Lari, Barbara ;
Bambi, Riccardo ;
Perri, Alessandro ;
Manneschi, Matteo ;
Terenzi, Giovanni ;
Liotti, Irene ;
Ciotta, Giovanni ;
Taddei, Cristina ;
Benucci, Maurizio ;
Casprini, Patrizia ;
Veneziani, Francesca ;
Fabbri, Sergio ;
Pompetti, Adolfo ;
Manfredi, Mariangela .
JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (09) :1671-1675
[35]   Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples [J].
Jaaskelainen, Anne J. ;
Kekalainen, Eliisa ;
Kallio-Kokko, Hannimari ;
Mannonen, Laura ;
Kortela, Elisa ;
Vapalahti, Olli ;
Kurkela, Satu ;
Lappalainen, Maija .
EUROSURVEILLANCE, 2020, 25 (18) :11-18
[36]  
Jia X, 2020, CLIN SIGNIFICANCE IG, DOI 10.1101/2020.02.28.20029025
[37]   Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019 [J].
Jin, Yujiao ;
Wang, Miaochan ;
Zuo, Zhongbao ;
Fan, Chaoming ;
Ye, Fei ;
Cai, Zhaobin ;
Wang, Ying ;
Cui, Huaizhong ;
Pan, Kenu ;
Xu, Aifang .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 94 :49-52
[38]  
Korth J, 2020, J CLIN VIROL, V128, DOI 10.1016/j.jcv.2020.104437
[39]  
Krishna S., 2020, RAPID DEV COVID 19 R
[40]  
Lassauniere R, 2020, MEDRXIV, DOI [DOI 10.1101/2020.04.09.20056325, 10.1101/2020.04.09.20056325]